DOCSLIB.ORG

October 12 – 16, 2019 Barcelona, Spain

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
October 12 – 16, 2019 Barcelona, Spain Barcelona, Spain Annual Congress of the European Association of Nuclear Medicine October 12 – 16, 2019 Barcelona, Spain eanm19.eanm.org Visit us on .com/officialEANM Technologist Abstract Book Technologist PUBLISHER CONTENT European Association of Nuclear Medicine No responsibility is taken for the correctness of this Schmalzhofgasse 26, 1060 Vienna, Austria information. Information as per date of printing. Phone: +43 1 890 44 27 | Fax: +43 1 890 44 27 - 9 Email: [email protected] | URL: www.eanm.org LAYOUT & DESIGN Barbora Trnena, EANM Executive Office EDITORS PRINT Andrea Santos, Chair EANM Technologist Committee MarieClaire Attard, EANM Technologist Committee Print Alliance HAV Produktions GmbH, Marius Mada, EANM Technologist Committee 2540 Bad Vöslau Barbora Trnena, EANM Executive Office WORLD LEADING MEETING EANM'19 TECHNOLOGIST ABSTRACT BOOK TECHNOLOGIST SESSIONS on the occassion of the 32nd Annual Congress of the European Association of Nuclear Medicine, CCIB, Barcelona, Spain | October 12 – 16, 2019 Technologist Committee Chair A. Santos (Portugal) Vice Chair L. Camoni (Italy) Members C. Terwinghe (Belgium) S. Rep (Slovenia) S. Rac (Croatia) M.C. Attard (Netherlands) A. Pietrzak (Poland) M. Mada (United Kingdom) Senior Advisor P. Fragoso Costa (Germany) Technologist Committee Interest Group Meeting: Tuesday, October 15, 2019, 13:00 - 14:30, Level P1, Hall 117 OCTOBER 13 – 17, 2019 | BARCELONA, SPAIN 3 EANM’19 WORLD LEADING MEETING TECHNOLOGIST ABSTRACT BOOK Table of Contents Message from the Technologist Committee 7 Contents Technologist Awards 2018 8 Programme 10 SUNDAY, OCTOBER 13, 2019 CTE 1 - with ANZSNM/CAMRT - Technologist Approach to Global Dose Optimization Dose Optimization Principles Pedro Fragoso Costa (Essen, Germany) 16 Dose Reference Levels in Nuclear Medicine Elizabeth A. Bailey (Sydney, Australia / ANZSNM) 17 PET/CT Dose Optimization and Occupational Exposure Tina M. Alden (Vancouver, Canada / CAMRT) 18 Cardiac Imaging Methods for Dose Reduction Luca Camoni (Brescia, Italy) 19 CTE Session 2 - Interactive - with the Radiation Protection Committee - Risk and Incidents Risks and Incidents in Nuclear Medicine - A Medical Physics Perspective Klaus Bacher (Ghent, Belgium) 22 Potential Risk and Incidents in HotLab Aljaz Socan (Ljubljana, Slovenia) 23 Management of Risks and Incidents in Nuclear Medicine Giorgio Testanera (London, United Kingdom) 24 Mini Course 1 - Research Methodology Research Methodology for Technologists Christina Malamateniou (London, United Kingdom) 26 Mini Course 2 - Interactive - Stress Testing for Technologists Stress Testing for Technologists MarieClaire Attard (Zwolle, Netherlands) 28 Mini Course 3 - Theranostics - Fundamental General Aspects of Theranostics in Nuclear Medicine Siroos Mirzaei (Vienna, Austria) 30 Theranostics for Technologists in the Context of NET Nick Gulliver (London, United Kingdom) 31 MONDAY, OCTOBER 14, 2019 Technologist Oral Presentations 1 32 Technologist e-Poster Presentations 1- 4 33 4 OCTOBER 12 – 16, 2019 | BARCELONA, SPAIN WORLD LEADING MEETING EANM’19 TECHNOLOGIST ABSTRACT BOOK CTE 3 - Preclinical Studies, from Bench to Bedside How to Develop the Ideal Radiopharmaceutical Contents Guy Bormans (Leuven, Belgium) 46 Preclinical PET Imaging and Quantification Michel Koole (Leuven, Belgium) 47 Nanobody Applications for Radionuclide Imaging and Therapy - Process from Camel to Patient Marleen Keyaerts (Brussels, Belgium) 48 CTE 4 - with SNMMI - Technologist's Guide Launch - Radiopharmacy: An Update Technologist's Guide Launch MarieClaire Attard (Zwolle, Netherlands) 50 Generators used in Nuclear Medicine Mark Crosthwaite (Richmond, United States of America / SNMMI) 51 Theoretical Basics of Radiopharmacy Zéna Wimana (Brussels, Belgium) 52 TUESDAY, OCTOBER 15, 2019 Technologist Oral Presentations 2 53 Technologist Oral Presentations 3 54 CTE 5 - Interactive - Patient Communication Health Communication through Design Thinking and Idea Reframing Débora Miranda (Lisbon, Portugal) 56 Patient Welfare and Advocacy - A View from the Inside Martin Lee (London, United Kingdom) 57 Risk Communication - Why and How to Communicate about Ionizing Radiation? Tanja Perko (Mol, Belgium) 58 CTE 6 - Parathyroid Imaging Comparison of [99mTc]Tc-MIBI and [18F] Fluorocholin Scintigraphy in Localization of Hyperfunctioning Parathyroid Tissue Luka Lezaic (Ljubljana, Slovenia) 60 [11C]Methionine PET-CT Imaging in Hyperparathyroidism Giovanna Pepe (Milan, Italy), Giorgio Testanera (London, United Kingdom) 61 The role of a technologist in the preparation of acquisition protocols and the processing of image data in Nuclear Medicine Parathyroid Imaging Sebastijan Rep (Ljubljana, Slovenia) & Giorgio Testanera (London, United Kingdom) 62 WEDNESDAY, OCTOBER 16, 2019 CTE 7 - Updates in Lung Imaging New PET Radiotracers for Lung Imaging Domenico Albano (Brescia, Italy) 64 Metabolic Volumes Delineation for External Beam Radiotherapy and its Prognostic Role in Lung Cancer Witold Cholewinski (Poznan, Poland) 65 Radiomic Features in Non-Small-Cell Lung Cancer FDG-PET/CT Studies Margarita Kirienko (Milan, Italy) 66 OCTOBER 12 – 16, 2019 | BARCELONA, SPAIN 5 Join the TECHNOLOGIST COMMITTEE INTEREST GROUP MEETING Tuesday, October 15, 2019 | 13:00 - 14:30, Level P1, Hall 117 eanm19.eanm.org WORLD LEADING MEETING EANM’19 TECHNOLOGIST ABSTRACT BOOK Join the TECHNOLOGIST Dear Colleagues COMMITTEE INTEREST GROUP MEETING and Friends, It is with great satisfaction and happiness that I welcome you to the 32nd Annual Congress of the EANM in Barcelona, Spain. The European Association of Nuclear Medicine Mirroring the international outreach of Technologist Committee (EANM-TC) is very proud the EANM-TC, sessions will be held with the of the diverse and up-to-date programme that participation of representatives from the Society it is offering at the congress. From Oct 12 to 16, of Nuclear Medicine and Molecular Imaging – 2019, a vast number of professionals from across Technologist Section (SNMMI-TS), the Canadian the entire world will come together at this unique Association of Medical Radiation Technologists event, creating an excellent opportunity to share (CAMRT) and the Australian and New Zealand knowledge and experience and to strengthen Society of Nuclear Medicine – Technologist Special bonds. Interest Group (ANZSNM-T). The focus of the technologist programme Three sessions of oral presentations and four is topics of great relevance for practice in the e-poster sessions have been organised to promote field of nuclear medicine, where scientific and the exchange of ideas and report on the work technological developments continue to be so that is being undertaken across the world. As an influential. The coverage ranges from preclinical additional motivating factor, awards will be given studies to theranostics, without neglecting the for the best two oral presentations as well as the importance of patient communication in the best two e-Poster Session presentations. practice of the nuclear medicine technologist. Finally, I highly recommend that you attend Following last year’s good experience, we will the Technologist Interest Group Meeting. During again be providing seven sessions of Continuous this meeting, the EANM-TC will share the current Technologist Education (CTE) and three Mini- endeavours of the Committee, as well as future Courses (MC) where specialists in each topic will perspectives. In addition, we will be announcing share their expertise and knowledge. There will the prize winners during this session! be scope for debating and active participation I wish you a great experience at the EANM through special interactive sessions. Congress. Bearing in mind all of the above events As a reflection of the multidisciplinary approach and activities, I truly believe that you will find it a adopted in the EANM-TC’s work, we will count most fruitful occasion. on the collaboration of the Radiation Protection Committee in the organisation of CTE 2. Also, a joint session with the EANM Neuroimaging Committee will take place during the Congress, With my best regards, aiming to cast light on the artefacts and pitfalls in Andrea Santos brain imaging (Pitfalls & Artefacts, session 5). Chair, EANM Technologist Committee OCTOBER 12 – 16, 2019 | BARCELONA, SPAIN 7 EANM’19 WORLD LEADING MEETING TECHNOLOGIST ABSTRACT BOOK EANM Congress Düsseldorf 2018 – Technologist Awards BEST ORAL PRESENTATION Awards Semi-quantitative criteria for the diagnosis of the myocarditis using 99mTc-Pyrophosphate SPECT/CT J. Ilyushenkova, S. Sazonova, K. Zavadovsky 2 ND NOMINEE FOR BEST ORAL PRESENTATION Usefulness of SPECT for the semiquantitative assessment of regional 123I MIBG myocardial uptake in heart failure: comparison between iterative reconstruction (OSEM) versus filtered back projection A. Ruzza, I. Andreoli, G. Romagna, P. Basile, L. Filippi, O. Bagni 3 RD NOMINEE FOR BEST ORAL PRESENTATION Comparison of Gastric Emptying Results Using 60min, 90min and 120min Protocol – A Retrospective Study D. Teixeira Maçarico, C. Laurins, A. Nicol BEST e-POSTER AWARD 99mTc-MAA SPECT/CT-based dosimetry in SIRT: Why personalized dosimetry matters – A retrospective study L. Esteves, B. Collette, E. El Darazi, G. Verset, V. Lucidi, S. Goldman, R. Moreno-Reyes 2 ND NOMINEE FOR BEST e-POSTER PRESENTATION Standardised Uptake Value & Hounsfield Unit in lumber spine & head of the femur for Alkaptonuria measured from 18F- NaF PET/CT bone scan E. H. M. A. Alawadhi, S. Vinjamuri, J. Gallagher, R. Lakshminarayan 3 RD NOMINEE FOR BEST e-POSTER PRESENTATION
Load more

Recommended publications
  • Assessment of Cardiac Amyloidosis with 99MTC- Pyrophosphate (PYP) Quantitative Spect
    Assessment of Cardiac Amyloidosis With 99MTC- pyrophosphate (PYP) Quantitative Spect Chao Ren Peking Union Medical College Hospital Jingyun Ren Peking Union Medical College Hospital Zhuang Tian Peking Union Medical College Hospital Yanrong Du Peking Union Medical College Hospital Zhixin Hao Peking Union Medical College Hospital Zongyao Zhang Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital Wei Fang Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital Fang Li Peking Union Medical College Hospital Shuyang Zhang Peking Union Medical College Hospital Bailing Hsu University of Missouri-Columbia Li Huo ( [email protected] ) Peking Union Medical College Hospital https://orcid.org/0000-0003-1216-083X Original research Keywords: ATTR cardiomyopathy, 99mTc-PYP quantitative SPECT, standardized uptake value, diagnostic feasibility, the operator reproducibility Posted Date: June 5th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-32649/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/25 Version of Record: A version of this preprint was published on January 7th, 2021. See the published version at https://doi.org/10.1186/s40658-020-00342-7. Page 2/25 Abstract Background: 99mTc-PYP scintigraphy provides differential diagnosis of ATTR cardiomyopathy (ATTR-CM) from lightchain cardiac amyloidosis and other myocardial disorders without biopsy. This study was aimed to assess the diagnostic feasibility and the operator reproducibility of 99mTc-PYP quantitative SPECT. Method:Thirty-seven consecutive patients underwent a99mTc-PYP thorax planar scan followed by SPECT and CT scans to diagnose suspected ATTR-CM were enrolled. For the quantitative SPECT, phantom studies were initially performed to determine the image conversion factor (ICF) and partial volume correction (PVC) factor to recover 99mTc-PYP activity concentration in myocardium for calculating the standardized uptake value (SUV) (unit: g/ml).
    [Show full text]
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Vizamyl, INN-Flutemetamol (18F)
    26 June 2014 EMA/546752/2014 Committee for Medicinal Products for Human Use (CHMP) Vizamyl flutemetamol (18F) Procedure No. EMEA/H/C/002553 Marketing authorisation holder: GE HEALTHCARE LIMITED Assessment report for an initial marketing authorisation application Assessment report as adopted by the CHMP with all commercially confidential information deleted 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Manufacturers ...................................................................................................... 8 1.3. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction......................................................................................................... 9 2.2. Quality aspects .................................................................................................. 11 2.2.1. Introduction ...................................................................................................
    [Show full text]
  • Recent Advances in Multi-Modality Molecular Imaging of Small Animals
    8/3/2016 Recent Advances in Multi-modality Molecular Imaging of Small Animals Benjamin M. W. Tsui, Ph.D. Department of Radiology August 3, 2016 1 Outline Introduction Early developments of molecular imaging (MI) of small animals (SA) Development of multi-modality MI of SA – Instrumentation – Image reconstruction and processing methods Recent advances Comparing Biomedical Imaging Techniques US MRI X-ray CT SPECT PET OPTICAL Anatomical Yes Yes Yes No No No Functional Yes Yes No Yes Yes Yes Resolution Sub- Sub- Sub- <1 mm ~1 mm Sub- millimeter millimeter millimeter (0.6 – 0.3mm) micron Molecular No Good No Excellent Excellent Excellent Target Molecular targeting No Poor No Good Excellent Poor sensitivity Translational Yes Yes Yes Yes Yes No 1 8/3/2016 Traditional Nuclear Medicine Imaging Techniques an important function imaging modality Activity labels tracer or biomarkers w/ radioisotope distribution administers radio-tracer into patient Gamma detects photon emissions using position- photons sensitive detectors Collimator Provides localization & biodistribution information of radiotracers - e.g., perfusion, potassium analog, monoclonal antibody Scintillation Clinical applications crystal Scintillation - e.g., cardiac and kidney functions, cancer Camera Positioning Photomultiplier detection, neurological disorders circuitry tube array EMISSION COMPUTED TOMOGRAPHY (ECT) an important function imaging modality Nuclear imaging combined with computed tomography (Image reconstruction from multiple projections) Categories of ECT - PET
    [Show full text]
  • Northern Ireland Nuclear Medicine Equipment Survey, 2017
    Northern Ireland nuclear medicine equipment survey 2017 Northern Ireland nuclear medicine equipment survey 2017 About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support. Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland © Crown copyright 2019 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third-party copyright information you will need to obtain permission from the copyright holders concerned. Published January 2019 PHE publications PHE supports the UN Sustainable Development Goals 2 Northern Ireland nuclear medicine equipment survey 2017 Contents Executive summary 4 Introduction 5 Methodology 6 Number of procedures performed 7 Procedures per scanner 8 Age of Scanners 9 Procedures reported for each organ or system 10 Procedures reported
    [Show full text]
  • October 2019 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Medicine Procedures, Radiopharmaceuticals, and Drugs
    WWW.SNMMI.ORG Final Rule 2020 Compared to October 2019 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Medicine Procedures, Radiopharmaceuticals, and Drugs October 2019 Rates CY 2020 Final Rule Updated April 2, 2020 Status Item/Code/Service OPPS Payment Status Indicator Services furnished to a hospital outpatient that are paid under a fee schedule or Not paid under OPPS. Paid by MACs under a fee schedule or payment system other than OPPS. payment system other than OPPS,* for example: A ● Separately Payable Clinical Diagnostic Laboratory Services (Not subject to Services are subject to deductible or coinsurance unless indicated otherwise. deductible or coinsurance.) D Discontinued Codes Not paid under OPPS or any other Medicare payment system. Items and Services: ● Not covered by any Medicare outpatient benefit category Not paid by Medicare when submitted on outpatient claims (any outpatient bill E1 ● Statutorily excluded by Medicare type). ● Not reasonable and necessary Items and Services: Not paid by Medicare when submitted on outpatient claims (any outpatient bill ● for which pricing information and claims data are not E2 type). available G Pass-Through Drug/ Biologicals Paid under OPPS; separate APC payment NonPass-Through Drugs and nonimplantable Biologicals, including Therapeutic Paid under OPPS; separate APC payment K Radiopharmaceuticals Paid under OPPS; payment is packaged into payment for other services. Items and Services packaged into APC rate N Therefore, there is no separate APC payment. Paid under OPPS; Addendum B displays APC assignments when services are separately payable. (1) Packaged APC payment if billed on the same claim as a HCPCS code STV-Packaged assigned status indicator “S,” “T,” or “V.” Q1 Codes (2) Composite APC payment if billed with specific combinations of services based on OPPS composite-specific payment criteria.
    [Show full text]
  • Preclinical SPECT Imaging Based on Compact Collimators and High Resolution Scintillation Detectors
    Preklinische SPECT-beeldvorming gebaseerd op compacte collimatoren en hogeresolutiescintillatiedetectoren Preclinical SPECT Imaging Based on Compact Collimators and High Resolution Scintillation Detectors Karel Deprez Promotoren: prof. dr. S. Vandenberghe, prof. dr. R. Van Holen Proefschrift ingediend tot het behalen van de graad van Doctor in de Ingenieurswetenschappen Vakgroep Elektronica en Informatiesystemen Voorzitter: prof. dr. ir. J. Van Campenhout Faculteit Ingenieurswetenschappen en Architectuur Academiejaar 2013 - 2014 ISBN 978-90-8578-672-6 NUR 954, 959 Wettelijk depot: D/2014/10.500/18 Department of Electronics and Information Systems Medical Image and Signal Processing (MEDISIP) Faculty of Engineering and Architecture Ghent University MEDISIP IBiTech Campus Heymans, Blok B De Pintelaan 185 9000 Ghent Belgium Promotors Prof. dr. Stefaan Vandenberghe Prof. dr. Roel Van Holen Board of examiners Prof. dr. ir. Patrick De Baets, Ghent University, chairman Dr. Michael Tytgat, Ghent University / CERN, secretary Prof. dr. Luc Van Hoorebeke, Ghent University Prof. dr. Dennis Schaart, Delft University of Technology, The Netherlands Prof. dr. Carlo Fiorini, Politecnico di Milano, Italy Dr. Samuel Espana˜ Palomares, Advanced Imaging Unit, Centro Nacional de Inves- tigaciones Cardiovasculares (CNIC), Spain Dr. Peter Bruyndonckx, Bruker MicroCT, Belgium This work was supported by the 7th Framework Programme (FP7) of the European Union through the SUBLIMA project (Grant Agreement No 241711) Acknowledgements The work presented in this dissertation started in 2008, shortly after the birth of my daughter, and was finished in early 2014. Before I started at the university I had been working for several years as a electronics design engineer at Barco and Gemidis. The first thing that struck me when I started at the university was the content of my work.
    [Show full text]
  • FDG PET for the Diagnosis of Dementia
    PET for Clinicians Christopher C. Rowe MD FRACP Austin Health University of Melbourne PET in dementia is not new but only in recent years, as PET has become more accessible, has a clinical role emerged. Austin Health, Melbourne does 1000 brain PET per year. Parieto-temporal hypometabolism in AD Clinical Diagnosis of AD • Sensitivity 80%, Specificity 70% (Knopfman, Neurology 2001- average of 13 studies with pathological confirmation) i.e. diagnosis requires dementia and only has moderate accuracy Mild Cognitive Impairment (MCI) does not equate to early AD • Only 50% of MCI will progress to AD dementia • 15-20% have other dementias. • 35-40% do not develop dementia. We need biomarkers for early diagnosis of AD and other dementias! New Research Criteria for AD (2007)* • dementia or significant functional impairment is NOT required • clear history of progressive cognitive decline • objective evidence from psychometric tests of episodic memory impairment • characteristic abnormalities in the CSF or in neuroimaging studies (MRI, FDG-PET, Aβ PET) *Dubois B, Feldman HH, Jacova C, et al. Lancet 2007. FDG PET in Alzheimer’s disease Parietotemporal hypometabolism Reiman EM et al. New Engl J Med 1996;334(12):752–758. View in AC-PC plane bottom of frontal lobe and occipital lobe on same horizontal plane in mid sagittal image Prefrontal Primary sensori-motor cortex Parietal Austin & Repatriation Medical Centre Department of Nuclear Medicine & Centre for PET Reading Brain PET Compare: • parietal vs sensori-motor and frontal • posterior cingulate vs
    [Show full text]
  • SNMMI Fact Sheet Amyloid.Indd
    Amyloid PET Imaging INDICATION: • Amyloid imaging radiopharmaceuticals are indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. RADIOPHARMACEUTICALS (FDA APPROVED): • 18F-Florbetapir (Amyvid™, Eli Lilly) • 18F-Florbetaben (NeuraCeq™, Piramal Life Sciences) • 18F-Flutemetamol (Vizamyl™, GE Healthcare) CONTRAINDICATIONS: • Inability to cooperate with PET brain imaging. • Amyloid PET imaging should be performed on a pregnant woman only if there is a clear clinical benefi t. • Previous reaction to the radiopharmaceutical or any excipient. ADVERSE REACTIONS (SEE INDIVIDUAL PACKAGE INSERT FOR COMPLETE LISTINGS): • 18-F Florbetapir (Amyvid™) - headache (<2%), dizziness, nausea (<1%), fatigue (<1%), injection site reaction (<1%). • 18F-Florbetaben (NeuraCeq™) - injection site reactions (<2%) consisting of erythema, irritation and pain. • 18F-Flutemetamol (Vizamyl™) - fl ushing (2%), blood pressure increase (2%), headache (1%), nausea (1%), dizziness (1%) STORAGE: • Store radiopharmaceutical at room temperature. • Radiopharmaceutical is provided in unit dose syringe and must not be diluted. PATIENT PREPARATION: • It is not necessary for patients to be NPO prior to imaging. • It is not necessary to control the post injection conditions (e.g. ambient light, temperature, noise). • It is not necessary to discontinue any medications. • Patient should wear comfortable clothing, with no metal on head (hair clips, earrings, etc.) • If patient is breast feeding, recommend discontinuation of breast feeding for 24 hours after administration of radiopharmaceutical. • It is often useful to engage a family member or caregiver in the process of explaining the scan procedure and assessing the patient’s ability to follow instructions.
    [Show full text]
  • Annual Report 2016 Department of Nuclear Medicine & PET-Centre, Aarhus University Hospital
    Moving Annual report 2016 Department of Nuclear Medicine & PET-Centre, Aarhus University Hospital Department of Nuclear Medicine & PET-Centre 2016 Nørrebrogade Building 3, Nørrebrogade , Building 10 Skejby TABLE OF CONTENTS Table of contents Preface ............................................................................................................................................................................................................................................................................................................. 1 Organisation.................................................................................................................................................................................................................................................................................................. 3 Department adresses........................................................................................................................................................................................................................................................................ 3 Organisation chart .............................................................................................................................................................................................................................................................................. 3 Staff .............................................................................................................................................................................................................................................................................................................
    [Show full text]
  • The Practice of Internal Dosimetry in Nuclear Medicine
    The Practice of Internal Dosimetry in Nuclear Medicine Series in Medical Physics and Biomedical Engineering Series Editors: John G Webster, E Russell Ritenour, Slavik Tabakov, and Kwan-Hoong Ng Other recent books in the series: Environmental Radioactivity and Emergency Preparedness Mats Isaksson and Christopher L. Rääf Radiation Protection in Medical Imaging and Radiation Oncology Richard J. Vetter and Magdalena S. Stoeva (Eds) Graphics Processing Unit-Based High Performance Computing in Radiation Therapy Xun Jia and Steve B. Jiang (Eds) Statistical Computing in Nuclear Imaging Arkadiusz Sitek The Physiological Measurement Handbook John G Webster (Ed) Radiosensitizers and Radiochemotherapy in the Treatment of Cancer Shirley Lehnert Diagnostic Endoscopy Haishan Zeng (Ed) Medical Equipment Management Keith Willson, Keith Ison, and Slavik Tabakov Targeted Muscle Reinnervation: A Neural Interface for Artificial Limbs Todd A Kuiken; Aimee E Schultz Feuser; Ann K Barlow (Eds) Quantifying Morphology and Physiology of the Human Body Using MRI L Tugan Muftuler (Ed) Monte Carlo Calculations in Nuclear Medicine, Second Edition: Applications in Diagnostic Imaging Michael Ljungberg, Sven-Erik Strand, and Michael A King (Eds) Vibrational Spectroscopy for Tissue Analysis Ihtesham ur Rehman, Zanyar Movasaghi, and Shazza Rehman Webb’s Physics of Medical Imaging, Second Edition M A Flower (Ed) Series in Medical Physics and Biomedical Engineering The Practice of Internal Dosimetry in Nuclear Medicine Michael G. Stabin Vanderbilt University Nashville, Tennessee, USA Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2017 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S.
    [Show full text]
  • In This Issue and the Winners Are… View This Year’S List of Award Winners!
    ISSUE THREE n WWW.SNMMI.ORG/VIRTUALPREVIEW2 In This Issue And The Winners Are… View this year’s list of award winners! Virtual Networking Receptions, Drink & Thinks, Movie Night, and more! Expected results. Delivered. Are you getting the most out of your Rb-82 Generator? The RUBY-FILL® Rubidium 82 Generator is clinically proven to deliver industry-leading efficiency with reliable consistency and dosing flexibility1-3 RUBY-FILL® has been proven to Consistently deliver expected yield with nearly 100% accuracy • In a recent study comparing currently available generators, RUBY-FILL® showed industry-leading efficiency3 Deliver highly accurate patient doses • Over the life of the generator, the deviation of delivered dose vs. requested dose approached 0%3 Provide clinical flexibility • RUBY-FILL® provides a long shelf life and flexible, patient-specific dosing1 Seem unbelievable? Visit Jubilant Radiopharma at the SNMMI Virtual Meeting Online July 11- 13 to see for yourself Indication for Use: RUBY-FILL is a closed system used to produce rubidium (Rb-82) chloride injection for intravenous use. Rubidium (Rb-82) chloride injection is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease. New Important Safety Information April 2019 Please note changes in Boxed Warning, Dosage and Administration, Directions for Eluting Rubidium Rb 82 Chloride
    [Show full text]